Lexeo Therapeutics is a clinical-stage genetic medicine company based in New York City that aims to transform healthcare for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. The company focuses on advancing a robust pipeline of therapies through a stepwise development approach, utilizing early proof-of-concept, functional, and biomarker data. Lexeo is dedicated to leveraging pioneering science to explore innovative treatments and improve patient outcomes. The company emphasizes a hybrid work culture, balancing in-office collaboration with remote flexibility, and is committed to fostering a diverse and inclusive work environment that enriches the professional experience of its team members.